Moderna, Inc. (NASDAQ:MRNA) Stock Has Consensus Price Target of $113.75

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has earned a consensus rating of “Hold” from the twenty-five research firms that are currently covering the stock, Marketbeat Ratings reports. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $120.25.

A number of equities research analysts have recently weighed in on the company. Royal Bank Of Canada reissued a “sector perform” rating and issued a $130.00 target price on shares of Moderna in a research note on Wednesday, August 19th. William Blair lowered Moderna from an “outperform” rating to a “market perform” rating in a research report on Tuesday, October 27th. Brookline Capital Markets restated a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Piper Sandler reaffirmed an “overweight” rating and issued a $305.00 price target (up from $230.00) on shares of Moderna in a research note on Monday, November 9th. Finally, JPMorgan Chase & Co. boosted their price objective on Moderna from $77.00 to $102.00 and gave the company an “underweight” rating in a research report on Tuesday.

Read Our Latest Stock Report on MRNA

Recent Moderna Headlines

Here are a few of the latest headlines about MRNA:

  • Positive Sentiment: Moderna’s personalized melanoma vaccine, used with Merck’s Keytruda, reduced the risk of recurrence or death in a Phase 3 trial. The results support the potential of its oncology pipeline, although positive trial news has not prevented the recent pullback. Article: Moderna's Cancer Vaccine Worked
  • Positive Sentiment: A report says Morgan Stanley sees potential for substantial share-price appreciation, offering a more optimistic view amid recent volatility. Article: Morgan Stanley Forecasts Strong Price Appreciation
  • Negative Sentiment: Investors are concerned that Moderna’s 2027 cash costs could reach $4 billion. The spending burden, alongside uncertain revenue from its expanding vaccine and oncology pipeline, raises questions about funding its next phase of growth. Article: Moderna's 2027 Cash Costs

Moderna Price Performance

Shares of Moderna stock opened at $194.18 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. Moderna has a 52-week low of $22.28 and a 52-week high of $280.80. The company has a fifty day moving average of $207.87 and a 200-day moving average of $100.37. The stock has a market capitalization of $78.57 billion, a price-to-earnings ratio of -27.35 and a beta of 1.16.

Moderna (NASDAQ:MRNA – Get Free Report) last posted its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. During the same period in the previous year, the firm posted ($0.51) earnings per share. The firm’s revenue for the quarter was up 29.2% on a year-over-year basis. Equities research analysts expect that Moderna will post -5.40 EPS for the current year.

Insider Transactions at Moderna

In related news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at $7,985,343.75. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $144.13, for a total transaction of $5,807,574.22. Following the sale, the president owned 1,525,858 shares of the company’s stock, valued at $219,921,913.54. This represents a 2.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 275,626 shares of company stock worth $50,776,076. Insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Several large investors have recently modified their holdings of MRNA. CENTRAL TRUST Co boosted its stake in shares of Moderna by 36.5% during the 3rd quarter. CENTRAL TRUST Co now owns 172 shares of the company’s stock valued at $33,000 after purchasing an additional 46 shares in the last quarter. Prestige Wealth Management Group LLC increased its position in shares of Moderna by 36.5% during the third quarter. Prestige Wealth Management Group LLC now owns 187 shares of the company’s stock valued at $36,000 after buying an additional 50 shares during the period. Costello Asset Management INC raised its stake in Moderna by 7.3% in the third quarter. Costello Asset Management INC now owns 966 shares of the company’s stock worth $186,000 after buying an additional 66 shares in the last quarter. Physician Wealth Advisors Inc. raised its stake in Moderna by 8.3% in the third quarter. Physician Wealth Advisors Inc. now owns 886 shares of the company’s stock worth $171,000 after buying an additional 68 shares in the last quarter. Finally, Fortitude Family Office LLC raised its stake in Moderna by 53.1% in the third quarter. Fortitude Family Office LLC now owns 222 shares of the company’s stock worth $43,000 after buying an additional 77 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

(Get Free Report)

Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

Further Reading

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.